H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $14 from $30 and keeps a Buy rating on the shares after the company announced that the AFFIRM-AL trial did not show statistical significance on the survival benefit, the primary endpoint for the study. The firm removed birtamimab from the current valuation but says PRX012 remains on track.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue